510(k) · Cleared
ClearedSerum Crosslaps One Step Elisa
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Osteometer Biotech A/S · JMM Column Chromatography & Color Development, Hydroxyproline
Cleared on Jul 9, 1999 as substantially equivalent to K972788 (Devices and Diagnostics Consulting Group, 1998) after a 116-day review. Its family tree reaches back 2 generations to 1996. 6 later devices descend from it.
- Decided
- Jul 9, 1999
- Review
- 116 days
- Class
- Class I
- Product code
- JMM
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 2 generations to K960171 (1996). 6 later devices descend from it, 1 citing it directly.
- Root · 2 generations backK960171 Active Crosslaps ElisaDiagnostic Systems Laboratories, Inc. · 1996
- 1 generation backK972788 Crosslaps ElisaDevices and Diagnostics Consulting Group · 1998
- This deviceK990843 Serum Crosslaps One Step ElisaOsteometer Biotech A/S · 1999
- Descendant · cites it directly · 5 of its ownK993706 Elecsys Serum B-Crosslaps/Serum ImmunoassayRoche Diagnostics Corp. · 2000 · Recalled
- Descendant · 2 generations on · 4 of its ownK051543 Elecsys Precicontrol BoneRoche Diagnostics Corp. · 2005
- Descendant · 3 generations on · 3 of its ownK111506 Elecsys Precicontrol Varia 3Roche Diagnostics · 2011 · Recalled
- Descendant · 4 generations on · 2 of its ownK132828 Elecsys Calcitonin; Immunoassay, Calset, Calcheck 5; Elecsys…Roche Diagnostics · 2013
- Descendant · 5 generations on · 0 of its ownK252431 Elecsys CalcitoninRoche Diagnostics GmbH · 2026
Showing 5 of 6 descendants. See all descendants
Descendants cleared per year
Most influential descendants
Showing 5 of 6 · See all- K993706Elecsys Serum B-Crosslaps/Serum ImmunoassayRoche Diagnostics Corp. · 2000 · cites it directly5descendants
- K051543Elecsys Precicontrol BoneRoche Diagnostics Corp. · 2005 · 2 generations on4descendants
- K111506Elecsys Precicontrol Varia 3Roche Diagnostics · 2011 · 3 generations on3descendants
- K132828Elecsys Calcitonin; Immunoassay, Calset, Calcheck 5; Elecsys Precicontrol Varia 3Roche Diagnostics · 2013 · 4 generations on2descendants
- K252431Elecsys CalcitoninRoche Diagnostics GmbH · 2026 · 5 generations on0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | K960171 | Active Crosslaps Elisa | Diagnostic Systems Laboratories, Inc. | 1996 | — |
| −1 | K972788 | Crosslaps Elisa | Devices and Diagnostics Consulting Group | 1998 | — |
| 0 (this device) | K990843 | Serum Crosslaps One Step Elisa | Osteometer Biotech A/S | 1999 | — |
| +1 | K993706 | Elecsys Serum B-Crosslaps/Serum Immunoassay | Roche Diagnostics Corp. | 2000 | 1 |
| +2 | K051543 | Elecsys Precicontrol Bone | Roche Diagnostics Corp. | 2005 | — |
| +3 | K111506 | Elecsys Precicontrol Varia 3 | Roche Diagnostics | 2011 | 1 |
| +4 | K132828 | Elecsys Calcitonin; Immunoassay, Calset, Calcheck 5; Elecsys Precicontrol… | Roche Diagnostics | 2013 | — |
| +5 | K252431 | Elecsys Calcitonin | Roche Diagnostics GmbH | 2026 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2000 | 1 | 0 |
| 2005 | 1 | 0 |
| 2011 | 1 | 0 |
| 2013 | 1 | 0 |
| 2018 | 1 | 0 |
| 2026 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in JMM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K972788 | Crosslaps ElisaSummary page 2…ive measurement of Type I Collagen C-telopeptides in plasma and serum is substantially equivalent to CrossLaps™ ELISA that was cleared by FDA in a previous submission (#K972788). This pre-market notification includes clinical data demonstrating that The CrossLaps™ ELISA assay is intended for in vitro dia… | 1998 |
What descends from it? (6)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K993706 | Elecsys Serum B-Crosslaps/Serum Immunoassay | 2000 | 5 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 3 years and passes through 3 companies; a new generation was cleared every 2.7 years on median.
- None of the 2 ancestors has a recall.
- Of its descendants, K993706 (Roche Diagnostics Corp., 2000) has gone furthest, with 5 descendants of its own.
How does its category compare?
All JMM devicesJMM Column Chromatography & Color Development, Hydroxyproline: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · JMM
FDA has decided no JMM device since 2007.
Median 510(k) review, days · JMM
Too few JMM 510(k)s in any year since 2007 to give a median.
Recalls per year · JMM
1in 2012
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · JMM
1in 2025
MAUDE reports naming product code JMM, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 1 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 0 | — | 0 | 0 |
| 2019 | 0 | — | 0 | 1 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 1 |
| 2022 | 0 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 1 |
| 2024 | 0 | — | 0 | 1 |
| 2025 | 0 | — | 0 | 1 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The Serum CrossLaps™ One Step ELISA assay is intended for in vitro diagnostic use as an indication of human bone resorption and may be used as an aid in : A. Monitoring bone resorption changes of 1.) Anti-resorptive therapies in postmenopausal women: a) Hormone Replacement Therapies (HRT) with hormones and hormone like drugs b) Bisphosphonate therapies 2.) Anti-resorptive therapies in individuals diagnosed with osteopenia, a) Hormone Replacement…
Read the full statement (106 words)
The Serum CrossLaps™ One Step ELISA assay is intended for in vitro diagnostic use as an indication of human bone resorption and may be used as an aid in :
A. Monitoring bone resorption changes of
1.) Anti-resorptive therapies in postmenopausal women:
a) Hormone Replacement Therapies (HRT) with hormones and hormone like drugs
b) Bisphosphonate therapies
2.) Anti-resorptive therapies in individuals diagnosed with osteopenia,
a) Hormone Replacement Therapies (HRT) with hormones and hormone like drugs
b) Bisphosphonate therapies
B. Predicting skeletal Response (Bone Mineral Density) in postmenopausal woman under
going anti-resorptive therapies
a) Hormone Replacement Therapies (HRT) with hormones and hormone like drugs
b) Bisphosphonate therapies
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K990843 · printed Nov 6, 2026
Cite this page
510(k) Report. “K990843: Serum Crosslaps One Step Elisa.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K990843
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026